Dimitri F. Dimitriou, MSC, Chief Executive Officer of ImmuPharma is talking about the company, its most successful drugs and new listing on Brussels. ImmuPharma is a drug development company which has been around 20 years now. The company started with close collaboration with the french Institution for National Research (CNRS) and then developed drugs based on received information on the discovery stage. The portfolio is focusing on the area includes immunology, autoimmune diseases. The drugs they have on the most advanced stage is for the relatively rare disease which is called lupus. It's an autoimmune disease which is often deadly.

The company listed his stock on Brussels in December 2019 to trades in Euro. Dmitri says that Brussels has a very good vibrant and cosmopolitan community within the sector. ImmuPharma is rather unique in the biotech world because of outsourced drug development and semi-virtual structure to keep the costs low. And they focus on the niche area of the relatively rare diseases.